Inhibition of pathogenic agents including α6β1...

Details Inhibition of pathogenic agents including α6β1... Inhibition of pathogenic agents including α6β1...

2006-05-25

2010-11-23

Haddad, Maher M (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C514S002600

Reexamination Certificate

active

07838000

ABSTRACT:
Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6β1 integrin receptors and/or α6β4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6β1 integrin receptors and α6β4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.

REFERENCES:
patent: 5266328 (1993-11-01), Skubitz et al.
patent: 5538725 (1996-07-01), Imhof
patent: 5567440 (1996-10-01), Hubbell et al.
patent: RE36844 (2000-08-01), Jones et al.
patent: 6114316 (2000-09-01), Ramamurthy et al.
patent: 6294356 (2001-09-01), Jones et al.
patent: 2002/0058336 (2002-05-01), Ashkar
patent: 2002/0160497 (2002-10-01), Montano et al.
patent: 2002/0168363 (2002-11-01), Feige et al.
patent: 2003/0044899 (2003-03-01), Tryggvason et al.
patent: 2003/0044913 (2003-03-01), Yue et al.
patent: 2003/0091569 (2003-05-01), Gerritsen et al.
patent: 2003/0100529 (2003-05-01), Tryggvason et al.
patent: 2003/0108540 (2003-06-01), Kalluri
patent: WO 02/30465 (2002-04-01), None
Cochlovius et al. Therapeutic Antibodies, after years of promise, magic bullets appear to be on the upswing. Modern Drug discovery, 2003, pp. 33-34 and 37-38.
Abstract of Article—Form and function: The laminin family of heterotrimers, Holly Colognato and Peter D. Yurhenco from interscience.wiley.com (2 pages) originally in Developmental Dynamics, vol. 218, Issue 2, 2000, pp. 213-234.
Abstract of Article—High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival, K. Friedrichs, P. Ruiz, F. Franke, I. Gille, H. J. Terpe, and B. A. Imhof from cancerres.aacrjournals.org (3 pages) originally in Cancer Research, vol. 51, Issue 4, pp. 901-906.
Abstract of Article—Identification of integrin-dependent and -independent cell adhesion domains in COOH-terminal globular region of laminin-5 alpha 3 chain, H. Mizushima, H. Takamura, Y. Miyagi, Y. Kikkawa, N. Yamanaka, H. Yasumitus, K. Misugi, and K. Miyazaki from cgd.aacrjournals.org (4 pages) originally in Cell Growth & Differentiation, vol. 8, Issue 9, 1997, pp. 979-987.
Abstract of Article—Integrin activation controls metastasis in human breast cancer, B. Felding-Habermann, T. E. O'Toole, J. W. Smith, E. Fransvea, Z. M. Ruggeri, M. H. Ginsberg, P. E. Hughes, N. Pampori, S. J. Shattil, A. Saven, and B. M. Mueller from ncbi.nlm.nih.gov (2 pages) originally in Proc. Natl, Acad. Sci., vol. 98, No. 4, Feb. 13, 2001, pp. 1853-1858.
Abstract of Article—Integrin Laminin Receptors and Breast Carcinoma Progression, Kathleen L. Connor, Jun Chung, Robin E. Bachelder, Arthur M. Mercurio, Isaac Rabinovitz, Leslie M. Shaw, and Taneli Tani from infotrieve.com (1 page) originally in Journal of Mammary Gland Biology and Neoplasi, vol. 6, No. 3, 2001, pp. 299-309.
Abstract of Article—Localization of heparin binding activity in recombinant laminin G domain, U. Sung, J. J. O'Rear, and P. D. Yurchenco from ncbi.nlm.nih.gov (1 page) originally in Eur. J. Biochem., vol. 250, No. 1, Nov. 15, 1997, pp. 138-143.
Abstract of Article—Molecular cloning of the cDNA encoding human laminin A chain, T. Haaparanta, J. Uitto, E. Ruoslahti, and E. Engvall from ncbi.nlm.nih.gov (2 pages) originally in Matrix, vol. 11, No. 3, Jun. 1991, pp. 151-160.
Abstract of Article—The integrin alpha 6 beta 1 promotes the survival of metastatic human breast carcinoma cells in mice, U. M. Wewer, L. M. Shaw, R. Albrechtsen, and A. M. Mercurio from ajp.amjpathol.org (3 pages) originally in American Journal of Pathology, vol. 151, No. 5, 1997, pp. 1191-1198.
Article—A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer, Zhang et al., Clinical Cancer Research, vol, 8, Apr. 2002, pp. 1196-1205.
Article—A Unique Sequence of the Laminin a3 G Domain Binds to Heparin and Promotes Cell Adhesion through Syndecan-2 and -4, Atsushi Utani, Motoyoshi Nomizu, Hiroshi Matsuura, Kozue Kato, Takashi Kobayashi, Ushio Takeda, Shinichi Aota, Peter K. Nielsen, and Hiorshi Shinkai, from jbc.org (21 pages) originally in J. Biol. Chem., vol. 276, Issue 31, Aug. 3, 2001, pp. 28779-28788.
Article—Deposition of laminin 5 in epidermal wounds regulates integrin signaling and adhesion, Nguyen et al., Current Opinion in Cell Biology, vol. 12, 2000, pp. 554-562.
Article—Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form ofPseudomonasexotoxin A, Langenheim et al., Breast Cancer Research and Treatment, vol. 90, 2005, pp. 281-293.
Article—Differential Regulation of Cellular Adhesion and Migration by Recombinant Laminin-5 Forms With Partial Deletion or Mutation Within the G3 Domain of a3 Chain, Yoshinobu Kariya, Toshiaki Tsubota, Tomomi Hirosaki, Hiroto Mizushima, Wilma Puzon-McLaughlin, Yoshikazu Takada, and Kaoru Miyazaki, Journal of Cellular Biochemistry, vol. 88, 2003, pp. 506-520.
Article—From genes to protein structure and function: novel applications of computational approaches in the genomic era, Skolnick et al., Tibtech, vol. 18, Jan. 2000, pp. 34-39.
Article—Globular domains 4/5 of the laminin a3 chain mediate deposition of precursor laminin 5, Sigle et al., Journal of Cell Science, vol. 117, No. 19, May 12, 2004, pp. 4481-4494.
Article—Homozygous a6 integrin mutation in junctional epidermolysis bullosa with congenital duodenal artresia, Pulkkinen et al., Human Molecular Genetics, vol. 6, No. 5, 1997, pp. 669-674.
Article—Identification of Integrin-dependent and—independent Cell Adhesion Domains in COOH-Terminal Globular Region of Laminin-5 a3 Chain, Hiroto Mizushima, Hiroyuki Takamura, Yohei Miyagi, Yamato Kikkawa, Naoki Yamanaka, Hidetaro Yasumitsu, Kazuaki Misugi, and Kaoru Miyazaki, Cell Growth & Differentation, Vol. 6, Sep. 1997, pp. 979-987.
Article—IgG Autoantibodies in Patients with Anti-Epiligrin Cicatricial Pemphigoid Recognize the G Domain of the Laminin 5 a-Subunit, Lazarova et al., Clinical Immunology, vol. 101, No. 1, Oct. 2001, pp. 100-105.
Article—Immunosuppresive therapy, Barry D. Kahan, Immunology, vol. 4, 1992, pp. 553-560.
Article—Isolation and Activity of Proteolytic Fragment of Laminin-5 a3 Chain, Yoshiaki Tsubota, Hiroto Mizushima, Tomomi Hirosaki, Shouichi Higashi, Hidetaro Yasumitsu, and Kaoru Miyazaki, Biochemical and Biophysical Research Communications, vol. 278, 2000, pp. 614-620.
Article—Ligand binding to proteins: The binding landscape model, Miller et al., Protein Science, vol. 6, 1997, pp. 2166-2179.
Article—Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparain-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, Burgess et al., The Journal of Cell Biology, vol. 111, 1990, pp. 2129-2138.
Article—Processing of Laminin-5 and Its Functional Consequences: Role of Plasmin and Tissue-type Plasminogen Activator, Lawrence E. Goldfinger, M. Sharon Stack, and Jonathan C. R. Jones from jcb.org (28 pages) originally in J. Cell Biol., vol. 141, No. 1, Apr. 6, 1998, pp. 255-265.
Article—Prolactin Antagonist-endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer, Beck et al., Cancer Research, vol. 63, Jul. 1, 2003, pp. 3598-3604.
Article—Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and in Vivo by Integrin Blocking Antibodies, V. M. Weaver, O. W. Petersen, F. Wang, C. A. Larabell, P. Briand, C. Damsky, and M. J. Bissell from jcb.org (

Affiliated with

Also associated with

Rating

Inhibition of pathogenic agents including α6β1... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of pathogenic agents including α6β1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of pathogenic agents including α6β1... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4199657